Research programme: haematological disorders therapeutics - PhenomixAlternative Names: PHX 1117
Latest Information Update: 16 Jul 2016
At a glance
- Originator Phenomix Corporation
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Haematological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-disorders in USA
- 16 Jul 2004 Preclinical trials in Haematological disorders in USA (unspecified route)